Currently, the only long-acting HIV treatment available in the US is Viiv Healthcare’s Cabenuva, which is administered as a ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

The list includes dengue fever, chikungunya, leptospirosis and Valley fever, says University of Washington professor Peter ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

The CDC’s Timothy M. Uyeki, M.D., cautioned, however, that if the virus changes, and especially if it begins to infect pigs, ...